Molecular heterogeneity, an immunosuppressive microenvironment, less accessible targets
Use of immune checkpoint inhibitors comes with a variety of potential side effects
Adoptive cell therapy, bispecific antibodies, novel immunotherapies among numerous strategies
Treatment with tocilizumab and steroids is standard, but new therapies are emerging
